Structure Therapeutics is trading 10.53% up now at $44.63 after September 8, 2026 clinical updates showed aleniglipron delivering up to 16.2% mean weight loss at 72 weeks without a plateau.
- The company also reported up to 3.3% weight loss after one ACCG-2671 dose, no serious adverse events, and began multiple-dose testing.
- The clinical update is the clearest catalyst behind the rebound.